| Randomized controlled trials–a matter of design PM Spieth, AS Kubasch, AI Penzlin, BMW Illigens, K Barlinn, T Siepmann Neuropsychiatric disease and treatment, 1341-1349, 2016 | 387 | 2016 |
| Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2 … U Platzbecker, JM Middeke, K Sockel, R Herbst, D Wolf, CD Baldus, ... The Lancet Oncology 19 (12), 1668-1679, 2018 | 287 | 2018 |
| PET/MRI in head and neck cancer: initial experience I Platzek, B Beuthien-Baumann, M Schneider, V Gudziol, J Langner, ... European journal of nuclear medicine and molecular imaging 40, 6-11, 2013 | 163* | 2013 |
| Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1β expression and release SR Hofmann, AS Kubasch, C Ioannidis, A Rösen-Wolff, HJ Girschick, ... Clinical immunology 161 (2), 300-307, 2015 | 106 | 2015 |
| Current challenges and unmet medical needs in myelodysplastic syndromes U Platzbecker, AS Kubasch, C Homer-Bouthiette, T Prebet Leukemia 35 (8), 2182-2198, 2021 | 78 | 2021 |
| Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO) SR Hofmann, AS Kubasch, U Range, MW Laass, H Morbach, ... Rheumatology international 36, 769-779, 2016 | 78 | 2016 |
| A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome S Bondu, AS Alary, C Lefèvre, A Houy, G Jung, T Lefebvre, D Rombaut, ... Science Translational Medicine 11 (500), eaav5467, 2019 | 73 | 2019 |
| CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease JS Hecker, L Hartmann, J Rivière, MC Buck, M van der Garde, ... Blood, The Journal of the American Society of Hematology 138 (18), 1727-1732, 2021 | 68 | 2021 |
| Development of luspatercept to treat ineffective erythropoiesis AS Kubasch, P Fenaux, U Platzbecker Blood advances 5 (5), 1565-1575, 2021 | 50 | 2021 |
| The evolving landscape of biomarkers for anti-PD-1 or anti-PD-L1 therapy A Tunger, U Sommer, R Wehner, AS Kubasch, MO Grimm, MP Bachmann, ... Journal of Clinical Medicine 8 (10), 1534, 2019 | 50 | 2019 |
| Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents AS Kubasch, F Schulze, A Giagounidis, KS Götze, J Krönke, K Sockel, ... Leukemia 34 (4), 1182-1186, 2020 | 44 | 2020 |
| Laser Doppler assessment of vasomotor axon reflex responsiveness to evaluate neurovascular function ML Kubasch, AS Kubasch, J Torres Pacheco, SJ Buchmann, ... Frontiers in neurology 8, 251488, 2017 | 38 | 2017 |
| Setting fire to ESA and EMA resistance: new targeted treatment options in lower risk myelodysplastic syndromes AS Kubasch, U Platzbecker International Journal of Molecular Sciences 20 (16), 3853, 2019 | 27 | 2019 |
| AXL inhibition in macrophages stimulates host-versus-leukemia immunity and eradicates naïve and treatment-resistant leukemia I Tirado-Gonzalez, A Descot, D Soetopo, A Nevmerzhitskaya, A Schäffer, ... Cancer discovery 11 (11), 2924-2943, 2021 | 26 | 2021 |
| Iron overload and its impact on outcome of patients with hematological diseases GN Franke, AS Kubasch, M Cross, V Vucinic, U Platzbecker Molecular Aspects of Medicine 75, 100868, 2020 | 26 | 2020 |
| Oculocutaneous and ocular albinism AS Kubasch, M Meurer Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und Verwandte …, 2017 | 26* | 2017 |
| Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid … G Garcia-Manero, ES Winer, DJ DeAngelo, SR Tarantolo, DA Sallman, ... Journal of Clinical Oncology 40 (16_suppl), 7016-7016, 2022 | 22 | 2022 |
| Beyond the edge of hypomethylating agents: novel combination strategies for older adults with advanced MDS and AML AS Kubasch, U Platzbecker Cancers 10 (6), 158, 2018 | 21 | 2018 |
| Targeting health-related quality of life in patients with myelodysplastic syndromes–current knowledge and lessons to be learned EN Oliva, U Platzbecker, P Fenaux, G Garcia-Manero, TW LeBlanc, ... Blood reviews 50, 100851, 2021 | 20 | 2021 |
| Anti-CD123 targeted therapy with talacotuzumab in advanced MDS and AML after failing hypomethylating agents-final results of the Samba trial AS Kubasch, F Schulze, KS Götze, J Krönke, K Sockel, JM Middeke, ... Blood 132, 4045, 2018 | 19 | 2018 |
Uwe PlatzbeckerLeipzigVerified email at medizin.uni-leipzig.de
